<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JCT</journal-id><journal-title-group><journal-title>Journal of Cancer Therapy</journal-title></journal-title-group><issn pub-type="epub">2151-1934</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jct.2019.1010072</article-id><article-id pub-id-type="publisher-id">JCT-95884</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Management and Clinico-Pathologic Aspects of Non-Melanoma Skin Cancer of the Head and Neck: A Retrospective Institutional Based Study at the Egyptian National Cancer Institute
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ihab</surname><given-names>Samy Fayek</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mohammed</surname><given-names>Ahmed Rifaat</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Dalia</surname><given-names>Bilal Mohammed</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Surgical Oncology Department, National Cancer Institute, Cairo University, Egypt</addr-line></aff><aff id="aff2"><addr-line>Epidemiology and Statistics Department, National Cancer Institute, Cairo University, Egypt</addr-line></aff><pub-date pub-type="epub"><day>25</day><month>09</month><year>2019</year></pub-date><volume>10</volume><issue>10</issue><fpage>846</fpage><lpage>862</lpage><history><date date-type="received"><day>1,</day>	<month>October</month>	<year>2019</year></date><date date-type="rev-recd"><day>20,</day>	<month>October</month>	<year>2019</year>	</date><date date-type="accepted"><day>23,</day>	<month>October</month>	<year>2019</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background:
   Reviewing and analyzing the Clinico
  -
  pathologic aspects of non-melanoma skin cancer of the head and neck (NMSCHN), type of management, prognostic factors, and disease
  -
  free
   survival (DFS) in a period of 5 years at the National Cancer Institute
  —Cairo University—Egypt. <b>Materials and Methods: </b>A retrospective study of two hundred patients with NMSCHN 
  was 
  treated at the National Cancer Institute
  —Cairo University—Egypt from January 2008 to December 2012. The mean follow-up was 6 months (1
   
  -
   
  84 months). <b>Results: </b>117 males and 83 females with 90% ≥ 50 years old. The scalp (27.5%), the periorbital region (13%), the cheek (12.5%) and the nose (12.5%) are the main anatomical sites affected. BCC represented 71.5% with nodular type (79%) predominance; SCC represented 21% with GII (61.1%) the commonest grade. Surgery was the main modality of treatment (93%) with local flaps 
  only 
  (6
  3.9
  %) and 
  primar
  y
   closure (14.
  7
  %) were the main surgical options following wide local excision. Positive and close margins were detected in 23.5% of excised specimens. No significant association was found between disease
  -
  free
   survival (DFS) and pathology, treatment modality, the occurrence of complications or safety margin status. <b>Conclusion:</b> NMSCHN lesions should be surgically excised in specialized high volume centers with readily available peripheral margin control and should be operated by senior experienced surgeons.
 
</p></abstract><kwd-group><kwd>Basal Cell Carcinoma</kwd><kwd> Squamous Cell Carcinoma</kwd><kwd> Non-Melanoma Skin Cancer</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Non-melanoma skin cancer (NMSC) is the most common malignancy among Caucasians. NMSC principally comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), but includes a host of rarer skin tumors [<xref ref-type="bibr" rid="scirp.95884-ref1">1</xref>]. According to The National Cancer Registry in Egypt based on Data of 40,477 patients collected from Tanta Cancer Center retrospectively to form the largest population-based cancer registry in Egypt covering a period of 9 years, skin cancer incidence was calculated as 3.1% of all cancers in both sexes and 3.8% of all cancers in males based on population of Gharbia (as an indicator for rates in Egypt) and based on number of cases of each cancer type there [<xref ref-type="bibr" rid="scirp.95884-ref2">2</xref>]. In the Egyptian population, over 60% of NMSC could be attributed to sun exposure and approximately 45% to skin color [<xref ref-type="bibr" rid="scirp.95884-ref3">3</xref>]. More specifically the incidence of NMSC was addressed at the National Population-Based Cancer Registry Program (2008-2011) as 1.35% of all cancers in males and 1.24% of all cancers in females [<xref ref-type="bibr" rid="scirp.95884-ref4">4</xref>]. In settings such as developing countries where Moh’s Micrographic Surgery is not readily available, prediction of NMSC aggressive lesions based on preoperative information (age, immunosuppression status, and location) is critical not only for surgical planning but also for reducing recurrence risk by treating the lesion with sufficiently adequate margins. Several studies have attempted to create a risk scale or model for assessing preoperative risk for aggressive NMSCs [<xref ref-type="bibr" rid="scirp.95884-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref8">8</xref>]. In Egypt, few studies focused on NMSC, mostly with a limited number of patients and not specific to NMSCHN and not addressing many prognostic factors highlighted and evaluated in this study [<xref ref-type="bibr" rid="scirp.95884-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref12">12</xref>]. In other parts of the world, with almost similar climate to Egypt, skin cancer is a common cancer [<xref ref-type="bibr" rid="scirp.95884-ref13">13</xref>], with increasing incidence of SCC and Basosquamous carcinoma (BSC) [<xref ref-type="bibr" rid="scirp.95884-ref14">14</xref>]. This study will focus on Egyptian patients with non-melanoma skin cancer of the head and neck (NMSCHN) who presented, diagnosed and managed at the National Cancer Institute—Cairo University—Egypt.</p></sec><sec id="s2"><title>2. Materials and Methods</title><p>A retrospective study where all patients’ data with non-melanoma skin cancer of the head and neck (NMSCHN) diagnosed, admitted and managed at the National Cancer Institute—Cairo University—Egypt in the period from January 2008 to December 2012 were documented and analyzed regarding patients’ characteristics (age and sex), tumor characteristics (anatomical site, T stage and number of lesions), histopathology (type and grade), treatment modality (surgery &#177; adjuvant treatment or no interference), safety margin status (positive, close or negative), type of reconstruction and type of flap used, complications and recurrence(s) during a follow-up period ranging from 1 to 84 months with a mean follow-up of 6 months. Recurrence and Disease-free survival will be correlated statistically with different parameters.</p><sec id="s2_1"><title>2.1. Exclusion Criteria</title><p>&#183; Patients with NMSCHN who were managed outside our institute and were just referred for follow-up or for consultation.</p><p>&#183; Patients with Xeroderma pigmentosum.</p><p>&#183; Patients with melanoma skin cancer by histopathology.</p></sec><sec id="s2_2"><title>2.2. Statistical Method</title><p>Demographic data and survival outcome will be analyzed using SPSS statistical package version 20. Relations between qualitative data will be done using Chi-square test or Fisher’s exact test. Moreover, survival analyses will be done using Kaplan Meier’s method and Comparison between survival curves will be done using log-rank test. A p-value less than 0.05 will be considered significant.</p></sec></sec><sec id="s3"><title>3. Results</title><p>Two hundred patients with NMSCHN were involved in this retrospective study in the period from January 2008 to December 2012.</p><sec id="s3_1"><title>3.1. Patients’ Characteristics</title><p>&#183; Age: The age of the patients ranged between 5 and 90 years with the peak incidence in the sixth decade of life. 15.5% of patients were below or equal to the age of 50 while 84.5% were 51 years old or more (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>&#183; Sex: Male patients constituted 58.5% (117/200) of cases while females constituted 41.5% (83/200). Male to female ratio was about 1.4:1 (<xref ref-type="table" rid="table2">Table 2</xref>).</p></sec><sec id="s3_2"><title>3.2. Tumor Characteristics</title><p>&#183; Anatomical distribution of lesions: The main site affected was the scalp 27.5% (55/200), followed by the periorbital region 13% (26/200), while the cheek and nose were equally affected 12.5% (25/200) each. Two patients with BCC showed multiple lesions in different sites 1% (2/200) (<xref ref-type="table" rid="table3">Table 3</xref>).</p><p>&#183; T Stage: The majority of cases were T1 representing 52% of all cases (104/200) and T4 representing 4% (8/200) with tumor invasion to parotid gland and eye globe (<xref ref-type="table" rid="table4">Table 4</xref>).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Age distribution of patients with NMSCHN</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Age (years)</th><th align="center" valign="middle" >Number of patients</th><th align="center" valign="middle" >Percent (%)</th></tr></thead><tr><td align="center" valign="middle" >≤50</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >15.5</td></tr><tr><td align="center" valign="middle" >&gt;50</td><td align="center" valign="middle" >169</td><td align="center" valign="middle" >84.5</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >200</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Sex distribution of patients with NMSCHN</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Gender</th><th align="center" valign="middle" >Number of patients</th><th align="center" valign="middle" >Percent (%)</th></tr></thead><tr><td align="center" valign="middle" >Males</td><td align="center" valign="middle" >117</td><td align="center" valign="middle" >58.5</td></tr><tr><td align="center" valign="middle" >Females</td><td align="center" valign="middle" >83</td><td align="center" valign="middle" >41.5</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >200</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Anatomical site distribution of NMSCHN lesions</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Site</th><th align="center" valign="middle" >Number of patients</th><th align="center" valign="middle" >Percent (%)</th></tr></thead><tr><td align="center" valign="middle" >Scalp</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >27.5</td></tr><tr><td align="center" valign="middle" >Cheek</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >12.5</td></tr><tr><td align="center" valign="middle" >Auricle</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >Periorbital</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >13</td></tr><tr><td align="center" valign="middle" >Forehead</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >5</td></tr><tr><td align="center" valign="middle" >Upper lip</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >5.5</td></tr><tr><td align="center" valign="middle" >Lower lip</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle" >Nose</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >12.5</td></tr><tr><td align="center" valign="middle" >Neck</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >Nasolabial</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Temple</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >Post-auricular</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Pre-auricular</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Post auricular, scalp, nose</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.5</td></tr><tr><td align="center" valign="middle" >Forehead, nasolabial, lower lip</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.5</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >200</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Distribution of NMSCHN lesions according to T stage</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Stage</th><th align="center" valign="middle" >Number of patients</th><th align="center" valign="middle" >Percent (%)</th></tr></thead><tr><td align="center" valign="middle" >T1</td><td align="center" valign="middle" >104</td><td align="center" valign="middle" >52</td></tr><tr><td align="center" valign="middle" >T2</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >36</td></tr><tr><td align="center" valign="middle" >T3</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >T4</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >200</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><p>&#183; Number of Lesions: 94% (188/200) of patients presented with a single lesion, 1% (2/200) of patients presented with 2 lesions and 5% (10/200) with multiple lesions. 12 patients presented with two and more lesions where 8 of them BCC (two of them in different sites), 2 SCC and 2 were BSCC patients (<xref ref-type="table" rid="table5">Table 5</xref>).</p></sec><sec id="s3_3"><title>3.3. Tumor Histopathology: (Tables 6-8)</title><p>All lesions were pathologically examined preoperatively and postoperatively to confirm the diagnosis and determine the margin status. BCC was detected in 72.5% (145/200) of patients, SCC in and basosquamous were detected in 21% (42/200) and 6% (12/200) of patients, respectively (<xref ref-type="table" rid="table6">Table 6</xref>). The most common type of BCC was the nodular type representing 79% (113/200) of cases (<xref ref-type="table" rid="table7">Table 7</xref>). The most common grade among the fifty four patients with Squamous Cell Carcinoma (SCC) and Basosquamous Carcinoma (BSC) was grade II, moderately differentiated tumors represented 61.1% (33/54) of cases (<xref ref-type="table" rid="table8">Table 8</xref>).</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Distribution of patients with NMSCHN according to the number of Lesions per patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Number of lesions per patient</th><th align="center" valign="middle" >Number of patients</th><th align="center" valign="middle" >Percent (%)</th></tr></thead><tr><td align="center" valign="middle" >Single</td><td align="center" valign="middle" >188</td><td align="center" valign="middle" >94</td></tr><tr><td align="center" valign="middle" >Two lesions</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >Three or more</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >5</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >200</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Tumor histopathology of NMSCHN among the study population</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Tumor Histopathology</th><th align="center" valign="middle" >Number of patients</th><th align="center" valign="middle" >Percent (%)</th></tr></thead><tr><td align="center" valign="middle" >Basal cell carcinoma</td><td align="center" valign="middle" >143</td><td align="center" valign="middle" >71.5</td></tr><tr><td align="center" valign="middle" >Squamous cell carcinoma</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >21</td></tr><tr><td align="center" valign="middle" >Basosquamous</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >Adenocarcinoma</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.5</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >200</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Clinico-pathologic types of BCC</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Clinico-pathologic types</th><th align="center" valign="middle" >Number of patients</th><th align="center" valign="middle" >Percent (%)</th></tr></thead><tr><td align="center" valign="middle" >Nodular</td><td align="center" valign="middle" >113</td><td align="center" valign="middle" >79</td></tr><tr><td align="center" valign="middle" >Adenocystic</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >4.2</td></tr><tr><td align="center" valign="middle" >Superficial spreading</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.1</td></tr><tr><td align="center" valign="middle" >Pigmented</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >4.2</td></tr><tr><td align="center" valign="middle" >Morpheaform</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >4.2</td></tr><tr><td align="center" valign="middle" >Micronodular</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.4</td></tr><tr><td align="center" valign="middle" >Infiltrative</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.1</td></tr><tr><td align="center" valign="middle" >Keratotic</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2.8</td></tr><tr><td align="center" valign="middle" >Mixed nodular superficial</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.7</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >143</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table8" ><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> Histopathological Grades of Squamous Cell Carcinoma (SCC) and Basosquamous Carcinoma (BSC)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Grade</th><th align="center" valign="middle" >Number of patients</th><th align="center" valign="middle" >Percent (%)</th></tr></thead><tr><td align="center" valign="middle" >I</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >25.9</td></tr><tr><td align="center" valign="middle" >II</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >61.1</td></tr><tr><td align="center" valign="middle" >III</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >12.9</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap></sec><sec id="s3_4"><title>3.4. Treatment Modality: (<xref ref-type="table" rid="table9">Table 9</xref>)</title><p>Surgery was the only treatment modality in 93% (186/200) of patients, surgery followed by post-operative radiotherapy (PORT) in 2% (4/200) of patients, they had positive margins and were not candidates for re-excision because of reconstruction and proximity to the eye. One patient (0.5%) developed metastatic SCC and received adjuvant chemotherapy 3% (6/200) of patients developed local recurrence followed by lung metastasis they underwent surgical excision followed by radiotherapy then chemotherapy. Meanwhile, 3 patients with BCC (1.5%) received no treatment because they were locally advanced, elderly with co-morbidities and beyond treatment.</p></sec><sec id="s3_5"><title>3.5. Safety Margin Status: (<xref ref-type="table" rid="table1">Table 1</xref>0)</title><p>Peripheral margin control guided by intraoperative frozen section analysis (IFSA) was not used in all patients but most of them. Postoperative Histopathological examination of all surgically excised specimens was done (except for four patients where SM was not assigned) for histopathological confirmation of tumor type and to detect adequacy of the safety margins where all specimens’ margins were oriented by sutures. Margins of surgical excision were negative in 150 (76.5%), positive in 41 (20.9%) and close in 5 (2.6%) of postoperative specimens.</p></sec><sec id="s3_6"><title>3.6. Closure of the Defect and Type of Reconstruction: (<xref ref-type="table" rid="table1">Table 1</xref>1 &amp; <xref ref-type="table" rid="table1">Table 1</xref>2)</title><p>Most of the study population underwent reconstruction with local flaps only 126/197 (63.9%), in 14.7% of patients (29/197) primary closure only was successfully achieved. Among patients who underwent surgical excision the method</p><table-wrap id="table9" ><label><xref ref-type="table" rid="table9">Table 9</xref></label><caption><title> Treatment modality in patients with NMSCHN</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Treatment Modality</th><th align="center" valign="middle" >Number of patients</th><th align="center" valign="middle" >Percent (%)</th></tr></thead><tr><td align="center" valign="middle" >Surgery</td><td align="center" valign="middle" >186</td><td align="center" valign="middle" >93</td></tr><tr><td align="center" valign="middle" >Surgery + PORT</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Surgery + chemotherapy</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.5</td></tr><tr><td align="center" valign="middle" >All</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >No interference</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.5</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >200</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table10" ><label><xref ref-type="table" rid="table1">Table 1</xref>0</label><caption><title> Safety margin status in postoperative pathologically examined specimens</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Margin Status</th><th align="center" valign="middle" >Number of patients</th><th align="center" valign="middle" >Percent (%)</th></tr></thead><tr><td align="center" valign="middle" >Positive</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >20.9</td></tr><tr><td align="center" valign="middle" >Close</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2.6</td></tr><tr><td align="center" valign="middle" >Negative</td><td align="center" valign="middle" >150</td><td align="center" valign="middle" >76.5</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >196</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><p>of defect closure was not assigned in only one patient 1/197 (0.5%) due to inadequate patient operative documentation. Rotational flaps (Figures 4-6) were the most commonly used type of flaps for the reconstruction of post-excision defects in this study (28.3%) followed by advancement flaps (27%) (<xref ref-type="fig" rid="fig1">Figure 1</xref>) then forehead flaps (12.1%) (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></sec><sec id="s3_7"><title>3.7. Distribution of BCC and SCC in Relation to Different Factors</title><p>Regarding sex, number of lesions, treatment modality, occurrence of complications and safety margin status no statistically significance was detected in relation to the histopathological type of NMSCHN either BCC or SCC (after exclusion of other histopathological types) (<xref ref-type="table" rid="table1">Table 1</xref>3).</p><table-wrap id="table11" ><label><xref ref-type="table" rid="table1">Table 1</xref>1</label><caption><title> Methods used for closure of the defects following surgical excision of NMSCHN</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Type of closure</th><th align="center" valign="middle" >Number of patients</th><th align="center" valign="middle" >Percent (%)</th></tr></thead><tr><td align="center" valign="middle" >Primary closure</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >14.7</td></tr><tr><td align="center" valign="middle" >Secondry intention</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2.5</td></tr><tr><td align="center" valign="middle" >Graft (<xref ref-type="fig" rid="fig7">Figure 7</xref>)</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >9.7</td></tr><tr><td align="center" valign="middle" >Local flap</td><td align="center" valign="middle" >126</td><td align="center" valign="middle" >63.9</td></tr><tr><td align="center" valign="middle" >Free flap</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >Graft + local flap</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >7.7</td></tr><tr><td align="center" valign="middle" >Defect closure was not assigned</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.5</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >197</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table12" ><label><xref ref-type="table" rid="table1">Table 1</xref>2</label><caption><title> Types of local flaps used for reconstruction following surgical excision of NMSCHN (Figures 1-7)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Type of local flap</th><th align="center" valign="middle" >Number of patients</th><th align="center" valign="middle" >Percent (%)</th></tr></thead><tr><td align="center" valign="middle" >Advancement</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >27</td></tr><tr><td align="center" valign="middle" >Bilobed (<xref ref-type="fig" rid="fig2">Figure 2</xref>)</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.1</td></tr><tr><td align="center" valign="middle" >Cervicofachial</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.1</td></tr><tr><td align="center" valign="middle" >Forehead</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >12.1</td></tr><tr><td align="center" valign="middle" >Glabellar</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >3.5</td></tr><tr><td align="center" valign="middle" >Rhomboid</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >5.7</td></tr><tr><td align="center" valign="middle" >Random</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.7</td></tr><tr><td align="center" valign="middle" >Estlander flap</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.4</td></tr><tr><td align="center" valign="middle" >Rotational</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >28.3</td></tr><tr><td align="center" valign="middle" >Transposition</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.1</td></tr><tr><td align="center" valign="middle" >V-Y flap</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >7.8</td></tr><tr><td align="center" valign="middle" >Nasolabial</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2.8</td></tr><tr><td align="center" valign="middle" >Karapandzic flap</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >4.3</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >141</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table13" ><label><xref ref-type="table" rid="table1">Table 1</xref>3</label><caption><title> Distribution of BCC and SCC in relation to different factors and its significance</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Factor</th><th align="center" valign="middle" >BCC</th><th align="center" valign="middle" >SCC</th><th align="center" valign="middle" >Total</th><th align="center" valign="middle" >p-value</th></tr></thead><tr><td align="center" valign="middle" >Sex Male Female Total</td><td align="center" valign="middle" >79 64 143</td><td align="center" valign="middle" >31 11 42</td><td align="center" valign="middle" >110 75 185</td><td align="center" valign="middle" >0.031</td></tr><tr><td align="center" valign="middle" >Number of lesions Single Multiple Total</td><td align="center" valign="middle" >135 8 143</td><td align="center" valign="middle" >41 1 42</td><td align="center" valign="middle" >176 9 185</td><td align="center" valign="middle" >0.395</td></tr><tr><td align="center" valign="middle" >Treatment modality Surgery Surgery plus adjuvant therapy No interference Total</td><td align="center" valign="middle" >134 6 3 143</td><td align="center" valign="middle" >39 3 0 42</td><td align="center" valign="middle" >173 9 3 185</td><td align="center" valign="middle" >0.481</td></tr><tr><td align="center" valign="middle" >Complication No complication Total</td><td align="center" valign="middle" >3 136 139</td><td align="center" valign="middle" >2 40 42</td><td align="center" valign="middle" >5 176 181</td><td align="center" valign="middle" >0.367</td></tr><tr><td align="center" valign="middle" >Safety margins Positive Close Negative Total</td><td align="center" valign="middle" >31 3 105 139</td><td align="center" valign="middle" >5 1 36 42</td><td align="center" valign="middle" >36 4 141 181</td><td align="center" valign="middle" >0.335</td></tr></tbody></table></table-wrap></sec><sec id="s3_8"><title>3.8. Recurrence (Locoregional/Distant): (<xref ref-type="table" rid="table1">Table 1</xref>4)</title><p>Fifty patients developed loco-regional recurrence. Out of the 50 patients who developed loco-regional recurrences, 45 developed single recurrence and 5 developed repeated recurrences. 9 patients developed regional lymph nodes</p><table-wrap id="table14" ><label><xref ref-type="table" rid="table1">Table 1</xref>4</label><caption><title> Correlation between different factors and recurrence among NMSCHN patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Recurrence</th><th align="center" valign="middle" >No recurrence</th><th align="center" valign="middle" >Total</th><th align="center" valign="middle" >p-value</th></tr></thead><tr><td align="center" valign="middle" >Age ≤50 years &gt;50 years Total</td><td align="center" valign="middle" >13 37 50</td><td align="center" valign="middle" >18 132 150</td><td align="center" valign="middle" >31 169 200</td><td align="center" valign="middle" >0.18</td></tr><tr><td align="center" valign="middle" >Sex Male Female Total</td><td align="center" valign="middle" >24 26 50</td><td align="center" valign="middle" >93 57 147</td><td align="center" valign="middle" >117 83 200</td><td align="center" valign="middle" >0.082</td></tr><tr><td align="center" valign="middle" >Number of lesions Single Multiple Total</td><td align="center" valign="middle" >43 7 50</td><td align="center" valign="middle" >145 5 150</td><td align="center" valign="middle" >188 12 200</td><td align="center" valign="middle" >0.007</td></tr><tr><td align="center" valign="middle" >T stage T1 T2 T3 T4 Total</td><td align="center" valign="middle" >25 19 3 3 50</td><td align="center" valign="middle" >79 53 13 5 150</td><td align="center" valign="middle" >104 72 16 8 200</td><td align="center" valign="middle" >0.771</td></tr><tr><td align="center" valign="middle" >Treatment modality Surgery Surgery plus adjuvant therapy Total</td><td align="center" valign="middle" >40 10 50</td><td align="center" valign="middle" >146 1 147</td><td align="center" valign="middle" >186 11 197</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >Pathology BCC BSC Total</td><td align="center" valign="middle" >30 13 43</td><td align="center" valign="middle" >115 31 146</td><td align="center" valign="middle" >145 44 189</td><td align="center" valign="middle" >0.25</td></tr><tr><td align="center" valign="middle" >Grade for SCC and BSC G I G II G III Total</td><td align="center" valign="middle" >4 10 6 20</td><td align="center" valign="middle" >10 23 1 34</td><td align="center" valign="middle" >14 33 7 54</td><td align="center" valign="middle" >0.008</td></tr><tr><td align="center" valign="middle" >Safety margins Positive Close Negative Total</td><td align="center" valign="middle" >26 2 22 50</td><td align="center" valign="middle" >15 3 128 146</td><td align="center" valign="middle" >41 5 150 196</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >PO complications Complications No complications Total</td><td align="center" valign="middle" >4 46 50</td><td align="center" valign="middle" >3 143 146</td><td align="center" valign="middle" >7 189 196</td><td align="center" valign="middle" >0.051</td></tr></tbody></table></table-wrap><p>metastasis. 6 patients of them were SCC and 3 patients were BSC. Those patients underwent neck dissection. During follow-up 6 SCC, patients developed pulmonary metastasis.</p><p>Many independent prognostic factors were found to significantly affect the recurrence rate among patients with NMSCHN. Patients aged more than 50 years old (p-value = 0.18), patients with multiple lesions (p-value = 0.007), patients with high grade of SCC or BSC (p-value = 0.008), patients with positive and close margins (p-value = 0.001), patients subjected to surgery + adjuvant therapy (p-value = 0.001) and patients who showed PO complications (p-value = 0.051), all those, showed significantly higher recurrence rate in relation to the rest of the study population. Other factors as T stage, sex of patients and BCC vs. BSC pathology didn’t show a significant increase in recurrence rate among the study population (<xref ref-type="table" rid="table1">Table 1</xref>4).</p></sec><sec id="s3_9"><title>3.9. Disease-Free Survival (DFS): (<xref ref-type="table" rid="table1">Table 1</xref>5)</title><p>Disease free survival ranged from 10.5 to 29.5 months with a median of 20 months. Regarding age, sex, T stage, treatment modality, occurrence of complications, histopathology (BCC vs. SCC) and safety margins; none of those factors showed a statistically significant correlation with Disease-free Survival (DFS).</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>To our knowledge, this study is by far the largest one in Egypt addressing non-melanoma skin cancer of the head and neck (NMSCHN), regarding the number of patients and the period of follow up which extended up to 84 months. The incidence of non-melanoma skin cancer is still rising worldwide [<xref ref-type="bibr" rid="scirp.95884-ref15">15</xref>], this increase can be, in part, attributed to the increase in the elderly population, in addition, many patients develop more than one non-melanoma skin cancer after the first one [<xref ref-type="bibr" rid="scirp.95884-ref16">16</xref>]. In this study, patients over 50 years old represented 84.5% of the study population (mean 60, 6 years with the peak incidence in the sixth decade) in whom recurrence rate was significantly higher (p-value = 0.18), similarly some studies on NMSC detected a peak incidence in the sixth decade of life [<xref ref-type="bibr" rid="scirp.95884-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref18">18</xref>], others in the seventh decade [<xref ref-type="bibr" rid="scirp.95884-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref20">20</xref>]. Male predominance was observed in this study as well as other studies [<xref ref-type="bibr" rid="scirp.95884-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref21">21</xref>], on the other hand, other studies of NMSC showed female predominance [<xref ref-type="bibr" rid="scirp.95884-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref20">20</xref>]. The male sex predilection of skin cancer in Egypt is explained by the fact that men represent the main workforce (outdoor work) with more risk for UV exposure than women [<xref ref-type="bibr" rid="scirp.95884-ref22">22</xref>]. NMSC most commonly occur in the head and neck region [<xref ref-type="bibr" rid="scirp.95884-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref25">25</xref>], and according to this study the scalp, nose and cheek are the most common anatomic sites for the occurrence of NMSCHN, according to Mahmoud et al., 2006 the cheek and nose [<xref ref-type="bibr" rid="scirp.95884-ref10">10</xref>], according to Rhee et al., 2008 the nose, cheek and eyelids [<xref ref-type="bibr" rid="scirp.95884-ref20">20</xref>], according to Al-Zou et al., 2016 the face (NOS), the eyelids and the ear [<xref ref-type="bibr" rid="scirp.95884-ref13">13</xref>], according</p><table-wrap id="table15" ><label><xref ref-type="table" rid="table1">Table 1</xref>5</label><caption><title> Correlation between different factors and DFS among NMSCHN patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Number of patients</th><th align="center" valign="middle" >Median Survival (mo.)</th><th align="center" valign="middle" >p-value</th></tr></thead><tr><td align="center" valign="middle" >Age ≤50 years &gt;50 years Total</td><td align="center" valign="middle" >31 165 196</td><td align="center" valign="middle" >36 20 20</td><td align="center" valign="middle" >0.177</td></tr><tr><td align="center" valign="middle" >Sex Male Female Total</td><td align="center" valign="middle" >114 82 196</td><td align="center" valign="middle" >12 20 20</td><td align="center" valign="middle" >0.4</td></tr><tr><td align="center" valign="middle" >T stage T1 T2 T3 T4 Total</td><td align="center" valign="middle" >102 71 16 7 196</td><td align="center" valign="middle" >20 12 48 20</td><td align="center" valign="middle" >0.112</td></tr><tr><td align="center" valign="middle" >Treatment modality Surgery Surgery plus adjuvant therapy Total</td><td align="center" valign="middle" >185 11 196</td><td align="center" valign="middle" >20 30 20</td><td align="center" valign="middle" >0.398</td></tr><tr><td align="center" valign="middle" >Pathology BCC SCC Total</td><td align="center" valign="middle" >139 42 181</td><td align="center" valign="middle" >20 30 20</td><td align="center" valign="middle" >0.927</td></tr><tr><td align="center" valign="middle" >Safety margins Positive Close Negative Total</td><td align="center" valign="middle" >41 5 149 195</td><td align="center" valign="middle" >12 6 36 20</td><td align="center" valign="middle" >0.187</td></tr><tr><td align="center" valign="middle" >PO complications Complications No complications Total</td><td align="center" valign="middle" >7 189 196</td><td align="center" valign="middle" >36 20 20</td><td align="center" valign="middle" >0.507</td></tr></tbody></table></table-wrap><p>to Marconi et al., 2016 the nose and face [<xref ref-type="bibr" rid="scirp.95884-ref26">26</xref>] and according to Zargaran et al., 2013 the nose, the cheek and the scalp [<xref ref-type="bibr" rid="scirp.95884-ref21">21</xref>] are the most common sites for occurrence of NMSCHN, noting that the nose is commonly affected in all the studies. T1 lesions represented the main T stage in this study (52%) while T2 represented 36% of lesions in the study population; this is in agreement with other studies [<xref ref-type="bibr" rid="scirp.95884-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref26">26</xref>]. Nodular type of BCC was by far the most common in this study population (79%) similarly other studies showed nodular type predominance in BCC [<xref ref-type="bibr" rid="scirp.95884-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref27">27</xref>]. Grade II for SCC and BSC was predominant in our study (61.1%) while Mahmoud et al., 2006 reported Grade I predominance (46.6%) [<xref ref-type="bibr" rid="scirp.95884-ref10">10</xref>]. Inspite Alternatives to the surgical management of cutaneous malignancies may be preferred under certain circumstances [<xref ref-type="bibr" rid="scirp.95884-ref11">11</xref>], Surgery remains the main line of treatment for NMSC [<xref ref-type="bibr" rid="scirp.95884-ref28">28</xref>], a recent meta-analysis comparing the different treatment modalities for NMSC demonstrated that surgical excision had superior outcomes when compared to cryotherapy, photodynamic therapy, radiotherapy, 5-flurouracil (5-FU), and imiquimod in terms of complete lesion response, clearance of NMSC, and cumulative recurrence probabilities [<xref ref-type="bibr" rid="scirp.95884-ref29">29</xref>]. 98.5% of our patients were operated upon as a part of the management strategy. It should be noted that head and neck skin cancers are particularly challenging to treat given the difficulty in determining the amount of tissue that should be excised to provide adequate cancer-free margins with the best functional and cosmetic outcome. In this study, we relied mainly on intra-operative frozen section analysis (IFSA) whenever available, unfortunately, it was not used in all our patients due to unavailability and sometimes due to surgeons’ reluctance leading to a high rate of positive margins (20.9%) with a significant recurrence rate (p = 0.001). Mohs Micrographic Surgery (MMS) is still not available at our institute, which was not considered a big concern by our team relying on a systemic review by Bath-Hextall et al., 2007 where surgical excision was compared to MMS and demonstrated no difference in 30-month recurrence rates in the treatment of BCC [<xref ref-type="bibr" rid="scirp.95884-ref30">30</xref>]. Similarly, no difference was found in the recurrence risk following treatment of recurrent BCC removed by surgical excision versus MMS [<xref ref-type="bibr" rid="scirp.95884-ref31">31</xref>]. A recent meta-analysis by Lansbury et al., 2013 indicated similar results for cutaneous SCC, signifying no difference between recurrence risk of surgical excision and MMS [<xref ref-type="bibr" rid="scirp.95884-ref32">32</xref>]. Although Bartos and Kullova 2018 stated that BCC and SCC had several clinicopathological differences and should be considered separately [<xref ref-type="bibr" rid="scirp.95884-ref33">33</xref>], our study didn’t show any significance regarding the distribution of both BCC and SCC in relation to different factors (<xref ref-type="table" rid="table1">Table 1</xref>3).</p><p>Since NMSC only very sporadically leads to metastases, one of the most adverse clinical features of disease is local tumor recurrence. This is a relatively frequent matter in a routine dermatologic practice. According to literature data, local recurrence rates range between 2% and 4.3% [<xref ref-type="bibr" rid="scirp.95884-ref34">34</xref>] [<xref ref-type="bibr" rid="scirp.95884-ref35">35</xref>], unfortunately the recurrence rate in this study was high up to 25% due to several factors including the anatomic sites of the lesions, the size (high risk lesions), the positive margins due to unavailability of IFSA and many patients were operated upon by young surgeons and senior residents.</p></sec><sec id="s5"><title>5. Conclusion</title><p>NMSCHN lesions should be surgically excised in specialized high volume centers with readily available peripheral margin control and should be operated by senior experienced surgeons.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Fayek, I.S., Rifaat, M.A. and Mohammed, D.B. (2019) Management and Clinico-Pathologic Aspects of Non-Melanoma Skin Cancer of the Head and Neck: A Retrospective Institutional Based Study at the Egyptian National Cancer Institute. Journal of Cancer Therapy, 10, 846-862. https://doi.org/10.4236/jct.2019.1010072</p></sec></body><back><ref-list><title>References</title><ref id="scirp.95884-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Lomas, A., Leonardi-Bee, J. and Bath-Hextall, F. (2012) A Systematic Review of Worldwide Incidence of Non-Melanoma Skin Cancer. British Journal of Dermatology, 166, 1069-1080. https://doi.org/10.1111/j.1365-2133.2012.10830.x</mixed-citation></ref><ref id="scirp.95884-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Elshikh, E.A., Anan, I., Ebaid, A.A., Al Gamal, D.A., Hamed, M.M. and Metry, A.B.S. (2015) A Retrospective Cross-Sectional Epidemiological Study. ISPOR 18th Annual European Congress, 18, A437.  
https://doi.org/10.1016/j.jval.2015.09.1059</mixed-citation></ref><ref id="scirp.95884-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">El Khwsky, F., Bedwani, R., D’Avanzo, B., Assaad, S., El Shafei Ali, A., Mokhtar, S. and La Vecchia, C. (1994) Risk Factors for Non-Melanomatous Skin Cancer in Alexandria, Egypt. International Journal of Cancer, 56, 375-378. 
https://doi.org/10.1002/ijc.2910560314</mixed-citation></ref><ref id="scirp.95884-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ibrahim, A.S., Khaled, H.M., Mikhail, N.N.H., Baraka, H. and Kamel, H. (2014) Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program. Journal of Cancer Epidemiology, 2014, Article ID: 437971.</mixed-citation></ref><ref id="scirp.95884-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Batra, R.S. and Kelley, L.C. (2002) Predictors of Extensive Subclinical Spread in Nonmelanoma Skin Cancer Treated with Mohs Micrographic Surgery. Archives of Dermatology, 138, 1043-1051. https://doi.org/10.1001/archderm.138.8.1043</mixed-citation></ref><ref id="scirp.95884-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Boyle, K., Newlands, S.D., Wagner Jr., R.F. and Resto, V.A. (2008) Predictors of Reconstruction with Mohs Removal of Nonmelanoma Skin Cancers. Laryngoscope, 118, 975-980. https://doi.org/10.1097/MLG.0b013e31816a8cf2</mixed-citation></ref><ref id="scirp.95884-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Rivera, A.E., Webb, J.M. and Cleaver, L.J. (2012) The Webb and Rivera (WAR) Score: A Preoperative Mohs Surgery Assessment Tool. Archives of Dermatology, 148, 206-210. https://doi.org/10.1001/archdermatol.2011.1352</mixed-citation></ref><ref id="scirp.95884-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Song, S.S., Goldenberg, A., Ortiz, A., Eimpunth, S., Oganesyan, G. and Jiang, S.I. (2016) Nonmelanoma Skin Cancer with Aggressive Subclinical Extension in Immunosuppressed Patients. JAMA Dermatology, 152, 683-690.  
https://doi.org/10.1001/jamadermatol.2016.0192</mixed-citation></ref><ref id="scirp.95884-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Hussein, M.R. (2005) Skin Cancer in Egypt: A Word in Your Ear. Cancer Biology &amp; Therapy, 4, 593-595. https://doi.org/10.4161/cbt.4.5.1730</mixed-citation></ref><ref id="scirp.95884-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Mahmoud, S.F., Sanad, E.M., Ageena, H.A., Fayed, N.M. and Mohamed, A.E. (2016) A Study of Non-Melanoma Skin Cancer in Benha District, Qalyubiyah Governorate, Egypt. Egyptian Dermatology Online Journal, 2, 12.</mixed-citation></ref><ref id="scirp.95884-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Mebed, A.H., Soliman, H.O., Gad, Z.S. and Abdel Hay, R.M. (2010) Multimodality Treatment for Non Melanoma Skin Cancer: A Prospective Study Done on 120 Egyptian Patients. Journal of the Egyptian National Cancer Institute, 22, 49-55.</mixed-citation></ref><ref id="scirp.95884-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Elsonbaty, M., Abdal-Rahim, M., Yaseen, O., Fikry, M., Radoan, A. and Abdelaal, M. (2012) Non-Melanoma Skin Carcinoma Versus Skin Carcinoma Complicating Xeroderma Pigmentosa, Egypt. Journal of Plastic, Reconstructive &amp; Aesthetic Surgery, 36, 125-130.</mixed-citation></ref><ref id="scirp.95884-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Al-Zou, A.B., Thabit, M.A., AlSakkaf, K.A. and Basaleem, H.O. (2016) Skin Cancer: Clinico-Pathological Study of 204 Patients in Southern Governorates of Yemen. Asian Pacific Journal of Cancer Prevention, 17, 3195-3199.</mixed-citation></ref><ref id="scirp.95884-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Saeid, R., Hosein, R., Mahshid, G., Yousef, K. and Hamid, S. (2015) Changing Trends of Types of Skin Cancer in Iran. Asian Pacific Journal of Cancer Prevention, 16, 4955-4958. https://doi.org/10.7314/APJCP.2015.16.12.4955</mixed-citation></ref><ref id="scirp.95884-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">National Comprehensive Cancer Network (2011) NCCN Clinical Practice Guidelines in Oncology. Basal Cell and Squamous Cell Skin Cancer.</mixed-citation></ref><ref id="scirp.95884-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wong, C.S.M., Strange, R.C. and Lear, J.T. (2003) Basal Cell Carcinoma. British Medical Journal, 327, 794-798. https://doi.org/10.1136/bmj.327.7418.794</mixed-citation></ref><ref id="scirp.95884-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Rao, J. and Deora, H. (2014) Surgical Excision with Forehead Flap as Single Modality Treatment for Basal Cell Cancer of Central Face: Single Institutional Experience of 50 Cases. Journal of Skin Cancer, 2014, Article ID: 320792.  
https://doi.org/10.1155/2014/320792</mixed-citation></ref><ref id="scirp.95884-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Hassan, M.I. and Hassan, D.A. (2012) Reconstruction after Removal of Basal Cell Carcinoma. Journal of American Science, 8, 42-49.</mixed-citation></ref><ref id="scirp.95884-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Igde, M., Yilanci, S., Bali, Y.Y., Unlu, R.E., Duzgun, S. and Pekdemir, I. (2015) Reconstruction of Tissue Defects Developing after Excision of Non-Melanoma Malignant Skin Tumors in Scalp and Forehead Regions. Turkish Neurosurgery, 25, 888-894. https://doi.org/10.5137/1019-5149.JTN.11773-14.0</mixed-citation></ref><ref id="scirp.95884-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Rhee, J.S., Davis-Malesevich, M., Logan, B.R., Neuburg, M., Burzynski, M. and Nattinger, A.B. (2008) Behavior Modification and Risk Perception in Patients with Nonmelanoma Skin Cancer. Wisconsin Medical Journal, 107, 62-68.</mixed-citation></ref><ref id="scirp.95884-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Zargaran, M., Moghimbeigi, A., Monsef, A.R., Teimourian, H. and Shojaei, S. (2013) A Clinicopathological Survey of Basal Cell Carcinoma in an Iranian Population. Journal of Dentistry of Shiraz University of Medical Sciences, 14, 170-177.</mixed-citation></ref><ref id="scirp.95884-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Hussein, M.R., Al-Badaiwy, Z.H. and Guirguis, M.N. (2004) Analysis of p53 and bcl-2 Protein Expression in the Nontumorigenic, Pretumorigenic, and Tumorigenic Keratinocytic Hyperproliferative Lesions. Journal of Cutaneous Pathology, 31, 643-651.  
https://doi.org/10.1111/j.0303-6987.2004.00244.x</mixed-citation></ref><ref id="scirp.95884-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Robson, M.C., Zachary, L.S., Schmidt, D.R., Faibisoff, B. and Hekmatpanah, J. (1989) Reconstruction of Large Cranial Defects in the Presence of Heavy Radiation Damage and Infection Utilizing Tissue Transferred by Microvascular Anastomoses. Plastic and Reconstructive Surgery, 83, 438-442.  
https://doi.org/10.1097/00006534-198903000-00004</mixed-citation></ref><ref id="scirp.95884-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Rogers, H.W., Weinstock, M.A., Harris, A.R., et al. (2010) Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006. Archives of Dermatology, 146, 283-287. https://doi.org/10.1001/archdermatol.2010.19</mixed-citation></ref><ref id="scirp.95884-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Alam, M. and Ratner, D. (2001) Cutaneous squamous-Cell Carcinoma. The New England Journal of Medicine, 344, 975-983.  
https://doi.org/10.1056/NEJM200103293441306</mixed-citation></ref><ref id="scirp.95884-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Marconi, D.G., Resende, B.D.C., Rauber, E., Soares, P.D.C., Fernandes, J.M., Mehta, N., Carvalho, A.L., Kupelian, P.A. and Chen, A. (2016) Head and Neck Non-Melanoma Skin Cancer Treated By Superficial X-Ray Therapy: An Analysis of 1021 Cases. PLoS ONE, 11, e0156544. https://doi.org/10.1371/journal.pone.0156544</mixed-citation></ref><ref id="scirp.95884-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Schnebelen, A.M., Gardner, J.M. and Shalin, S.C. (2016) Margin Status in Shave Biopsies of Nonmelanoma Skin Cancers Is It Worth Reporting? Archives of Pathology &amp; Laboratory Medicine, 140, 678-681.  
https://doi.org/10.5858/arpa.2015-0313-OA</mixed-citation></ref><ref id="scirp.95884-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Gualdi, G., Monari, P., Apalla, Z. and Lallas, A. (2015) Surgical Treatment of Basal Cell Carcinoma and Squamous Cell Carcinoma. Giornale Italiano di Dermatologia e Venereologia, 150, 435-447.</mixed-citation></ref><ref id="scirp.95884-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Lv, R. and Sun, Q. (2017) A Network Meta-Analysis of Non-Melanoma Skin Cancer (NMSC) Treatments: Efficacy and Safety Assessment. Journal of Cellular Biochemistry, 118, 3686-3695. https://doi.org/10.1002/jcb.26015</mixed-citation></ref><ref id="scirp.95884-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Bath-Hextall, F.J., Perkins, W., Bong, J. and Williams, H.C. (2007) Interventions for Basal Cell Carcinoma of the Skin. Cochrane Database of Systematic Reviews. 
https://doi.org/10.1002/14651858.CD003412.pub2</mixed-citation></ref><ref id="scirp.95884-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Smeets, N.W., Krekels, G.A., Ostertag, J.U., Essers, B.A., Dirksen, C.D., Nieman, F.H. and Neuman, H.A. (2004) Surgical Excision vs. Mohs’ Micrographic Surgery for Basal-Cell Carcinoma of the Face: Randomised Controlled Trial. The Lancet, 364, 1766-1772. https://doi.org/10.1016/S0140-6736(04)17399-6</mixed-citation></ref><ref id="scirp.95884-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Lansbury, L., Bath-Hextall, F., Perkins, W., Stanton, W. and Leonardi-Bee, J. (2013) Interventions for Nonmetastatic Squamous Cell Carcinoma of the Skin: Systematic Review and Pooled Analysis of Observational Studies. British Medical Journal, 347, f6153. https://doi.org/10.1136/bmj.f6153</mixed-citation></ref><ref id="scirp.95884-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Bartos, V. and Kullová, M. (2018) Non-Melanoma Skin Cancer: A Clinicopathological Study of Patients with Basal Cell Carcinoma and Squamous Cell Carcinoma. Klinicka Onkologie Journal, 31, 40-45. https://doi.org/10.14735/amko201840</mixed-citation></ref><ref id="scirp.95884-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Chren, M.M., Torres, J.S., Stuart, S.E., et al. (2011) Recurrence after Treatment of Nonmelanoma Skin Cancer: A Prospective Cohort Study. Archives of Dermatology, 147, 540-546. https://doi.org/10.1001/archdermatol.2011.109</mixed-citation></ref><ref id="scirp.95884-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J.S., Yi, J.H., Yun, S.K., Kim, H.-U. and Ihm, C.-W. (2010) Clinicohistopathological Study of Recurrent Basal Cell Carcinomas after Surgical Excision. Korean Journal of Dermatology, 48, 453-459.</mixed-citation></ref></ref-list></back></article>